BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 23482645)

  • 1. Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire.
    Casazza JP; Bowman KA; Adzaku S; Smith EC; Enama ME; Bailer RT; Price DA; Gostick E; Gordon IJ; Ambrozak DR; Nason MC; Roederer M; Andrews CA; Maldarelli FM; Wiegand A; Kearney MF; Persaud D; Ziemniak C; Gottardo R; Ledgerwood JE; Graham BS; Koup RA;
    J Infect Dis; 2013 Jun; 207(12):1829-40. PubMed ID: 23482645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.
    Lévy Y; Lacabaratz C; Lhomme E; Wiedemann A; Bauduin C; Fenwick C; Foucat E; Surenaud M; Guillaumat L; Boilet V; Rieux V; Bouchaud O; Girard PM; Molina JM; Morlat P; Hocqueloux L; Richert L; Pantaleo G; Lelièvre JD; Thiébaut R
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33568510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigenic competition in CD4
    Kallas EG; Grunenberg NA; Yu C; Manso B; Pantaleo G; Casapia M; Baden LR; Valencia J; Sobieszczyk M; Van Tieu H; Allen M; Hural J; Graham BS; Kublin J; Gilbert PB; Corey L; Goepfert PA; McElrath MJ; Johnson RP; Huang Y; Frahm N
    Sci Transl Med; 2019 Nov; 11(519):. PubMed ID: 31748227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.
    Gómez CE; Perdiguero B; García-Arriaza J; Cepeda V; Sánchez-Sorzano CÓ; Mothe B; Jiménez JL; Muñoz-Fernández MÁ; Gatell JM; López Bernaldo de Quirós JC; Brander C; García F; Esteban M
    PLoS One; 2015; 10(11):e0141456. PubMed ID: 26544853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine.
    Kundu SK; Katzenstein D; Moses LE; Merigan TC
    Proc Natl Acad Sci U S A; 1992 Dec; 89(23):11204-8. PubMed ID: 1360665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques.
    Mothe B; Hu X; Llano A; Rosati M; Olvera A; Kulkarni V; Valentin A; Alicea C; Pilkington GR; Sardesai NY; Rocafort M; Crespo M; Carrillo J; Marco A; Mullins JI; Dorrell L; Hanke T; Clotet B; Pavlakis GN; Felber BK; Brander C
    J Transl Med; 2015 Feb; 13():60. PubMed ID: 25879820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1-specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38-DR- phenotype: comparison of statistical methods for measurement.
    Lubaki NM; Shepherd ME; Brookmeyer RS; Hon H; Quinn TC; Kashamuka M; Johnson M; Gottle R; Devers J; Lederman HM; Bollinger RC
    J Acquir Immune Defic Syndr; 1999 Sep; 22(1):19-30. PubMed ID: 10534143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study.
    Li F; Finnefrock AC; Dubey SA; Korber BT; Szinger J; Cole S; McElrath MJ; Shiver JW; Casimiro DR; Corey L; Self SG
    PLoS One; 2011; 6(6):e20479. PubMed ID: 21695251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine.
    Gahery H; Daniel N; Charmeteau B; Ourth L; Jackson A; Andrieu M; Choppin J; Salmon D; Pialoux G; Guillet JG
    AIDS Res Hum Retroviruses; 2006 Jul; 22(7):684-94. PubMed ID: 16831093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection.
    Wilson SE; Pedersen SL; Kunich JC; Wilkins VL; Mann DL; Mazzara GP; Tartaglia J; Celum CL; Sheppard HW
    AIDS Res Hum Retroviruses; 1998 Jul; 14(11):925-37. PubMed ID: 9686639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A therapeutic HIV-1 vaccine enhances anti-HIV-1 immune responses in patients under highly active antiretroviral therapy.
    Tung FY; Tung JK; Pallikkuth S; Pahwa S; Fischl MA
    Vaccine; 2016 Apr; 34(19):2225-32. PubMed ID: 27002500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).
    Kibuuka H; Kimutai R; Maboko L; Sawe F; Schunk MS; Kroidl A; Shaffer D; Eller LA; Kibaya R; Eller MA; Schindler KB; Schuetz A; Millard M; Kroll J; Dally L; Hoelscher M; Bailer R; Cox JH; Marovich M; Birx DL; Graham BS; Michael NL; de Souza MS; Robb ML
    J Infect Dis; 2010 Feb; 201(4):600-7. PubMed ID: 20078213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.
    Catanzaro AT; Koup RA; Roederer M; Bailer RT; Enama ME; Moodie Z; Gu L; Martin JE; Novik L; Chakrabarti BK; Butman BT; Gall JG; King CR; Andrews CA; Sheets R; Gomez PL; Mascola JR; Nabel GJ; Graham BS;
    J Infect Dis; 2006 Dec; 194(12):1638-49. PubMed ID: 17109335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunodeficiency virus type 1 specific cytotoxic T lymphocyte responses in Chinese infected with HIV-1 B'/C Recombinant (CRF07_BC).
    Chen J; Hong K; Jia M; Liu H; Zhang Y; Liu S; Zhang X; Zhao H; Peng H; Ma P; Xing H; Ruan Y; Williams KL; Yu XG; Altfeld M; Walker BD; Shao Y
    Retrovirology; 2007 Aug; 4():62. PubMed ID: 17727734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.
    Fomsgaard A; Karlsson I; Gram G; Schou C; Tang S; Bang P; Kromann I; Andersen P; Andreasen LV
    Vaccine; 2011 Sep; 29(40):7067-74. PubMed ID: 21767590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8
    Li SS; Kochar NK; Elizaga M; Hay CM; Wilson GJ; Cohen KW; De Rosa SC; Xu R; Ota-Setlik A; Morris D; Finak G; Allen M; Tieu HV; Frank I; Sobieszczyk ME; Hannaman D; Gottardo R; Gilbert PB; Tomaras GD; Corey L; Clarke DK; Egan MA; Eldridge JH; McElrath MJ; Frahm N;
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28931520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-specific cytotoxic T-lymphocyte activity in immunologically normal HIV-infected persons.
    Bernard NF; Pederson K; Chung F; Ouellet L; Wainberg MA; Tsoukas CM
    AIDS; 1998 Nov; 12(16):2125-39. PubMed ID: 9833853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Immunogen Selectively Eliciting CD8
    Ishii H; Terahara K; Nomura T; Takeda A; Okazaki M; Yamamoto H; Tokusumi T; Shu T; Matano T
    J Virol; 2020 Mar; 94(8):. PubMed ID: 32024773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.